How should I evaluate and manage a patient with elevated hemoglobin, hematocrit, and white blood cell count?

Evaluation and Management of Elevated Hemoglobin, Hematocrit, and WBC Count

Begin by measuring serum erythropoietin (EPO) level and ordering JAK2 mutation testing immediately—these two tests will determine whether you're dealing with a primary myeloproliferative neoplasm (most critically polycythemia vera) versus secondary causes, which fundamentally changes management and prognosis. 1

Initial Diagnostic Approach

Step 1: Confirm True Erythrocytosis

First, verify the elevation is significant and persistent:

• Men: Hemoglobin >16.5 g/dL or hematocrit >49%
• Women: Hemoglobin >16 g/dL or hematocrit >48%
• Repeat CBC if borderline to confirm persistence 2

The evidence is clear that a single elevated value warrants investigation if accompanied by other concerning features (thrombocytosis, leukocytosis, splenomegaly, unusual thrombosis), but isolated borderline elevations can be rechecked in 3 months 1.

Step 2: Order Critical Tests Immediately

Essential first-line tests:

• Serum EPO level
• JAK2 V617F mutation testing
• Complete metabolic panel (assess renal function)
• Oxygen saturation
• Peripheral blood smear review 1, 2

The serum EPO level is your critical branch point:

• Low EPO = Primary erythrocytosis (>90% specific for polycythemia vera) 1
• Normal/High EPO = Secondary erythrocytosis (hypoxia, renal disease, tumors)

Step 3: Assess for Polycythemia Vera (PV)

PV diagnosis requires (per 2016 WHO criteria): 2

All 3 major criteria OR first 2 major + minor criterion:

Major criteria:

1. Hemoglobin >16.5 g/dL (men) or >16 g/dL (women), OR hematocrit >49% (men) or >48% (women)
2. Bone marrow biopsy showing hypercellularity with trilineage proliferation and pleomorphic mature megakaryocytes
3. JAK2 V617F or JAK2 exon 12 mutation present

Minor criterion:

• Subnormal serum EPO level

Critical pitfall: Do not skip bone marrow biopsy if JAK2 is positive and EPO is low—you need histologic confirmation to distinguish PV from other myeloproliferative neoplasms 2.

Risk Stratification and Management

If Polycythemia Vera is Confirmed:

Immediate risk stratification based on:

• Age ≥60 years = HIGH RISK
• Prior thrombosis = HIGH RISK
• Age <60 + no prior thrombosis = LOW RISK 3

LOW-RISK PV Management:

• Aspirin 81-100 mg daily (unless contraindicated)
• Phlebotomy to maintain hematocrit <45% (target may be 42% for women or those with residual vascular symptoms)
• NO cytoreductive therapy initially 3

HIGH-RISK PV Management:

• Aspirin 81-100 mg daily
• Phlebotomy to maintain hematocrit <45%
• Cytoreductive therapy with hydroxyurea (first-line)
• Consider ruxolitinib if hydroxyurea-resistant or intolerant 3

Hydroxyurea resistance/intolerance is defined as: 3

• Need for phlebotomy after 3 months of ≥2 g/day hydroxyurea, OR
• Uncontrolled myeloproliferation (platelets >400×10⁹/L AND WBC >10×10⁹/L) after 3 months, OR
• Development of cytopenias (ANC <1.0×10⁹/L, platelets <100×10⁹/L, or Hb <10 g/dL), OR
• Unacceptable toxicity (leg ulcers, mucocutaneous manifestations)

If Secondary Erythrocytosis (Normal/High EPO):

Systematically evaluate for:

1. Hypoxia-related causes (most common in young adults 4):

   • Chronic lung disease (COPD, sleep apnea)
   • Cyanotic heart disease
   • High altitude exposure
   • Heavy smoking (check carboxyhemoglobin)
   • Obesity hypoventilation syndrome

2. Renal causes:

   • Renal artery stenosis
   • Renal cysts or tumors
   • Post-renal transplant

3. Tumor-related EPO production:

   • Hepatocellular carcinoma
   • Renal cell carcinoma
   • Cerebellar hemangioblastoma
   • Uterine fibroids

4. Congenital causes (especially if young, family history):

   • High oxygen affinity hemoglobins
   • 2,3-BPG deficiency
   • VHL mutations
   • EPOR mutations

Targeted imaging based on clinical suspicion: Renal ultrasound, CT abdomen, sleep study as indicated 5, 6.

Addressing the Elevated WBC Count

The leukocytosis pattern matters critically:

If mature neutrophilia with PV: This is part of the myeloproliferative process—managed with the PV treatment above 2.

If concerning features present:

• Immature cells (blasts, promyelocytes) on smear
• WBC >25×10⁹/L without obvious infection
• Associated fever, weight loss, night sweats, bruising
• Lymphocytosis with atypical cells

→ Urgent hematology referral for possible acute leukemia or lymphoproliferative disorder 7, 8.

If reactive leukocytosis suspected:

• Infection (most common—look for fever, localizing symptoms)
• Medications (corticosteroids, G-CSF, lithium)
• Smoking, obesity
• Recent surgery, trauma, or stress
• Chronic inflammatory conditions

Repeat CBC with differential in 2-4 weeks if reactive cause identified and treated 7.

Critical Management Considerations

Thrombosis Prevention

PV patients have significantly elevated thrombotic risk. The combination of elevated hematocrit, thrombocytosis, and leukocytosis creates a prothrombotic state. Maintaining hematocrit <45% reduces cardiovascular death and major thrombosis 3.

Avoid Common Pitfalls

1. Don't rely on "derived" fibrinogen—always use Clauss method if coagulation assessment needed 9
2. Don't assume relative (spurious) polycythemia without proper evaluation—missed PV has serious consequences 1
3. Don't delay JAK2 testing waiting for other results—it can be done simultaneously with EPO 6
4. Don't ignore borderline elevations with other cytopenias or splenomegaly—these warrant full workup 1

When to Refer to Hematology

Immediate referral if:

• JAK2 mutation positive
• Low serum EPO level
• Splenomegaly on exam
• Thrombocytosis (>450×10⁹/L) accompanying erythrocytosis
• Immature cells on peripheral smear
• No clear secondary cause identified after initial workup 5, 8

Monitoring After Diagnosis

For confirmed PV:

• CBC every 1-2 weeks initially until hematocrit stable <45%
• Then CBC every 3 months
• Annual assessment for progression to myelofibrosis or acute leukemia
• Lifelong aspirin unless contraindicated 3

For secondary erythrocytosis:

• Treat underlying cause
• Monitor CBC every 3-6 months
• Consider phlebotomy if hematocrit >54% with hyperviscosity symptoms 10

This algorithmic approach prioritizes identifying life-threatening myeloproliferative neoplasms while efficiently evaluating secondary causes, ensuring appropriate risk stratification and evidence-based management to prevent thrombotic complications and disease progression.